Massimo Tortarolo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8654533/publications.pdf

Version: 2024-02-01

38 papers	1,904 citations	257450 24 h-index	330143 37 g-index
38 all docs	38 docs citations	38 times ranked	2741 citing authors

#	Article	IF	Citations
1	The p97â€Nploc4 ATPase complex plays a role in muscle atrophy during cancer and amyotrophic lateral sclerosis. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 2225-2241.	7.3	7
2	A Novel HGF/SF Receptor (MET) Agonist Transiently Delays the Disease Progression in an Amyotrophic Lateral Sclerosis Mouse Model by Promoting Neuronal Survival and Dampening the Immune Dysregulation. International Journal of Molecular Sciences, 2020, 21, 8542.	4.1	8
3	Spinal Cord Metabolic Signatures in Models of Fast- and Slow-Progressing SOD1G93A Amyotrophic Lateral Sclerosis. Frontiers in Neuroscience, 2019, 13, 1276.	2.8	14
4	RNS60 exerts therapeutic effects in the SOD1 ALS mouse model through protective glia and peripheral nerve rescue. Journal of Neuroinflammation, 2018, 15, 65.	7.2	33
5	Presymptomatically applied AMPA receptor antagonist prevents calcium increase in vulnerable type of motor axon terminals of mice modeling amyotrophic lateral sclerosis. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 1739-1748.	3.8	5
6	Altered Metabolic Profiles Associate with Toxicity in SOD1G93A Astrocyte-Neuron Co-Cultures. Scientific Reports, 2017, 7, 50.	3.3	20
7	Targeting Extracellular Cyclophilin A Reduces Neuroinflammation and Extends Survival in a Mouse Model of Amyotrophic Lateral Sclerosis. Journal of Neuroscience, 2017, 37, 1413-1427.	3.6	42
8	Multiple intracerebroventricular injections of human umbilical cord mesenchymal stem cells delay motor neurons loss but not disease progression of SOD1G93A mice. Stem Cell Research, 2017, 25, 166-178.	0.7	29
9	Amyotrophic Lateral Sclerosis, a Multisystem Pathology: Insights into the Role of TNFÎ±. Mediators of Inflammation, 2017, 2017, 1-16.	3.0	45
10	New Insights on the Mechanisms of Disease Course Variability in ALS from Mutant SOD1 Mouse Models. Brain Pathology, 2016, 26, 237-247.	4.1	56
11	Lack of TNFâ€alpha receptor type 2 protects motor neurons in a cellular model of amyotrophic lateral sclerosis and in mutant SOD1 mice but does not affect disease progression. Journal of Neurochemistry, 2015, 135, 109-124.	3.9	33
12	Longitudinal tracking of triple labeled umbilical cord derived mesenchymal stromal cells in a mouse model of Amyotrophic Lateral Sclerosis. Stem Cell Research, 2015, 15, 243-253.	0.7	19
13	Specific Induction of Akt3 in Spinal Cord Motor Neurons is Neuroprotective in a Mouse Model of Familial Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2014, 49, 136-148.	4.0	32
14	Human SOD1-G93A Specific Distribution Evidenced in Murine Brain of a Transgenic Model for Amyotrophic Lateral Sclerosis by MALDI Imaging Mass Spectrometry. Journal of Proteome Research, 2014, 13, 1800-1809.	3.7	21
15	Biocompatible fluorescent nanoparticles forin vivostem cell tracking. Nanotechnology, 2013, 24, 245603.	2.6	29
16	Mutant Copper-Zinc Superoxide Dismutase (SOD1) Induces Protein Secretion Pathway Alterations and Exosome Release in Astrocytes. Journal of Biological Chemistry, 2013, 288, 15699-15711.	3.4	216
17	A Mouse Model of Familial ALS Has Increased CNS Levels of Endogenous Ubiquinol9/10 and Does Not Benefit from Exogenous Administration of Ubiquinol10. PLoS ONE, 2013, 8, e69540.	2.5	14
18	Lentiviral vectors carrying enhancer elements of Hb9 promoter drive selective transgene expression in mouse spinal cord motor neurons. Journal of Neuroscience Methods, 2012, 205, 139-147.	2.5	23

#	Article	IF	Citations
19	Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2011, 12, 340-344.	2.1	30
20	Unraveling the Complexity of Amyotrophic Lateral Sclerosis: Recent Advances from the Transgenic Mutant SOD1 Mice. CNS and Neurological Disorders - Drug Targets, 2010, 9, 491-503.	1.4	31
21	Functional alterations of the ubiquitin-proteasome system in motor neurons of a mouse model of familial amyotrophic lateral sclerosisâ€. Human Molecular Genetics, 2009, 18, 82-96.	2.9	146
22	Translational Research in ALS. , 2008, , 267-310.		3
23	Erythropoietin does not preserve motor neurons in a mouse model of familial ALS. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 31-35.	2.1	21
24	Proteomic analysis of spinal cord of presymptomatic amyotrophic lateral sclerosis G93A SOD1 mouse. Biochemical and Biophysical Research Communications, 2007, 353, 719-725.	2.1	72
25	Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS. Molecular and Cellular Neurosciences, 2006, 31, 218-231.	2.2	92
26	Glutamate AMPA receptors change in motor neurons of SOD1G93A transgenic mice and their inhibition by a noncompetitive antagonist ameliorates the progression of amytrophic lateral sclerosis-like disease. Journal of Neuroscience Research, 2006, 83, 134-146.	2.9	104
27	Targeting Stress Activated Protein Kinases, JNK and p38, as New Therapeutic Approach for Neurodegenerative Diseases. Central Nervous System Agents in Medicinal Chemistry, 2006, 6, 109-117.	1.1	12
28	Inter- and Intracellular Signaling in Amyotrophic Lateral Sclerosis: Role of p38 Mitogen-Activated Protein Kinase. Neurodegenerative Diseases, 2005, 2, 128-134.	1.4	42
29	Expression of SOD1 G93A or wildâ€type SOD1 in primary cultures of astrocytes downâ€regulates the glutamate transporter GLTâ€1: lack of involvement of oxidative stress. Journal of Neurochemistry, 2004, 88, 481-493.	3.9	57
30	Activated p38MAPK Is a Novel Component of the Intracellular Inclusions Found in Human Amyotrophic Lateral Sclerosis and Mutant SOD1 Transgenic Mice. Journal of Neuropathology and Experimental Neurology, 2004, 63, 113-119.	1.7	81
31	Glial activation and TNFR-I upregulation precedes motor dysfunction in the spinal cord of mnd mice. Cytokine, 2004, 25, 127-135.	3.2	20
32	Kif1B? isoform is enriched in motor neurons but does not change in a mouse model of amyotrophic lateral sclerosis. Journal of Neuroscience Research, 2003, 71, 732-739.	2.9	12
33	Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Molecular and Cellular Neurosciences, 2003, 23, 180-192.	2.2	155
34	Expression of glutamate receptor subtypes in the spinal cord of control andmnd mice, a model of motor neuron disorder. Journal of Neuroscience Research, 2002, 70, 553-560.	2.9	25
35	Transgenic SOD1 G93A mice develop reduced GLTâ€1 in spinal cord without alterations in cerebrospinal fluid glutamate levels. Journal of Neurochemistry, 2001, 79, 737-746.	3.9	173
36	Differential Expression of S100Î² and Glial Fibrillary Acidic Protein in the Hippocampus after Kainic Acid-Induced Lesions and Mossy Fiber Sprouting in Adult Rat. Experimental Neurology, 2000, 161, 317-329.	4.1	31

#	Article	IF	Citations
37	Lack of apoptosis in mice with ALS. Nature Medicine, 1999, 5, 966-967.	30.7	90
38	Glutamate release in human cerebral cortex and its modulation by 5â€hydroxtryptamine acting at h 5â€HT 1D receptors. British Journal of Pharmacology, 1998, 123, 45-50.	5.4	61